Two new drugs against the most deadly Ebola fever showed in a study in Congo a so good effect, that the researchers intend to make all Patients available. The scientific journal Nature reported.
In the study, 90 percent of the patients had one of the two experimental preparations within three days after the appearance of the first signs of the disease survived. To carry this point in time, the Infected are still relatively few viruses in the blood. They were treated later, survived for an average of 15 percent.
The two successful agents bear the names of REGN-EB3 and mAB114. They were tested alongside two other medicines in 681 patients. After the evaluation of nearly 500, it was already clear that these two were the other two therapies significantly superior.
In the case of REGN-EB3, it is a combination of three so-called monoclonal antibodies. These Defense compounds are similar to those used by the human immune system. They are specialized to detect certain characteristics of the Virus and attack. mAB114 is derived from a single antibody was found in the case of a Survivor of an Ebola outbreak in the year 1995.
In the Democratic Republic of the Congo have fallen ill within the last twelve months, more than 2,800 people to Ebola and almost 1,900 died because of it. It is the worst Ebola outbreak since the years 2014 and 2015.